CAR-T cell trials have focused on Hodgkin lymphomas, results of 2 ALCL patients treated with CD30.CAR-Ts are promising and include one complete remission for 9 months without impaired virus-specific immunity (16). The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.